Application/Control Number: 10/533,051

Art Unit: 4161

DETAILED ACTION

Page 2

Status of Claims

1. Based on a preliminary amendment filed on 04/26/2005, Claims 9-12 and 21-28 have been canceled by Applicant. Claims 1-8 and 13-20 were previously presented.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7, drawn to a method of treating a cognitive impairment comprising providing a patient a composition containing at least one selective dopamine D1-like receptor agonist.

Group II, claim(s) 8, drawn to a method for generating a profile for correlating dopaminergic state to cognitive impairment.

Group III, claim(s) 13-20, drawn to a composition comprising at least one selective dopamine D1-like receptor agonist, (and, potentially, a D2 agonist) and a kit containing the said composition.

3. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Chausmer and Katz (Psychopharmacology, 2002) teach a composition comprising the dopamine D1-like receptor agonist, SKF 82958 (Abstract, Introduction 2nd paragraph).

Application/Control Number: 10/533,051 Page 3

Art Unit: 4161

4. This application contains claims directed to more than one species of the generic

invention. These species are deemed to lack unity of invention because they are not so linked as

to form a single general inventive concept under PCT Rule 13.1.

If Applicant elects Group I, a further species election is required:

• selective dopamine D1-like receptor agonist;

• second drug to be used in combination with the selective dopamine D1-like

receptor agonist; and,

o this may be a selective dopamine D2 receptor agonist, which must also be

specified

• the underlying disease causing cognitive impairment.

If Applicant elects Group II, no further species election is required:

If Applicant elects Group III, a further species election is required:

• selective dopamine D1-like receptor agonist; and,

• selective dopamine D2 receptor agonist.

Applicant is required, in reply to this action, to elect a single species to which the claims

shall be restricted if no generic claim is finally held to be allowable. The reply must also identify

the claims readable on the elected species, including any claims subsequently added. An

argument that a claim is allowable or that all claims are generic is considered non-responsive

unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of

claims to additional species which are written in dependent form or otherwise include all the

Application/Control Number: 10/533,051 Page 4

Art Unit: 4161

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

5. The claims are deemed to correspond to the species listed above in the following manner:

Group I: Claims 1-8 -- selective dopamine D1-like receptor agonist
Claims 3-6 -- second drug to be used with selective dopamine D1-like receptor agonist
Claims 2 -- underlying disease causing the cognitive impairment

Group III: Claims 13-20 -- selective dopamine D1-like receptor agonist Claims 14-16, 18-20 -- selective dopamine D2 receptor agonist

The following claim(s) are generic:

Group I: Claims 1-3 Group II: Claim 8

Group III: Claims 13, 14, 17, and 18

- 6. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Chausmer and Katz (Psychopharmacology, 2002) teach a composition comprising the dopamine D1-like receptor agonist, SKF 82958 (Abstract, Introduction 2nd paragraph), thereby showing the lack of a special technical feature.
- 7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Art Unit: 4161

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

9. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/533,051 Page 6

Art Unit: 4161

10. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to PAUL ZAREK whose telephone number is (571)270-5754. The

examiner can normally be reached on Monday-Thursday, 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, PATRICK NOLAN can be reached on 571-272-0847. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

PEZ

/Patrick J. Nolan/

Supervisory Patent Examiner, Art Unit 4161